@prefix bqmodel: <http://biomodels.net/model-qualifiers/> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix prism: <http://prismstandard.org/namespaces/basic/2.0/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .

<http://omex-library.org/BIOMD0000000666.omex> bqmodel:isDescribedBy <local:00001> ;
    prism:keyword "Biomodels" ;
    dc:description """<body xmlns="http://www.w3.org/1999/xhtml">
  <div class="dc:title">Pappalardo2016 - PI3K/AKT and MAPK Signaling
Pathways in Melanoma Cancer</div>
  <div class="dc:bibliographicCitation">
    <p>This model is described in the article:</p>
    <div class="bibo:title">
      <a href="http://identifiers.org/pubmed/27015094" title="Access to this publication">Computational Modeling of
    PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer.</a>
    </div>
    <div class="bibo:authorList">Pappalardo F, Russo G, Candido S,
  Pennisi M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F, Libra
  M.</div>
    <div class="bibo:Journal">PLoS ONE 2016; 11(3): e0152104</div>
    <p>Abstract:</p>
    <div class="bibo:abstract">
      <p>Malignant melanoma is an aggressive tumor of the skin and
    seems to be resistant to current therapeutic approaches.
    Melanocytic transformation is thought to occur by sequential
    accumulation of genetic and molecular alterations able to
    activate the Ras/Raf/MEK/ERK (MAPK) and/or the PI3K/AKT (AKT)
    signalling pathways. Specifically, mutations of B-RAF activate
    MAPK pathway resulting in cell cycle progression and apoptosis
    prevention. According to these findings, MAPK and AKT pathways
    may represent promising therapeutic targets for an otherwise
    devastating disease.Here we show a computational model able to
    simulate the main biochemical and metabolic interactions in the
    PI3K/AKT and MAPK pathways potentially involved in melanoma
    development. Overall, this computational approach may
    accelerate the drug discovery process and encourages the
    identification of novel pathway activators with consequent
    development of novel antioncogenic compounds to overcome tumor
    cell resistance to conventional therapeutic agents. The source
    code of the various versions of the model are available as S1
    Archive.</p>
    </div>
  </div>
  <div class="dc:publisher">
    <p>This model is hosted on 
  <a href="http://www.ebi.ac.uk/biomodels/">BioModels Database</a>
  and identified by: 
  <a href="http://identifiers.org/biomodels.db/MODEL1609190000">MODEL1609190000</a>.</p>
    <p>To cite BioModels Database, please use: 
  <a href="http://identifiers.org/pubmed/20587024" title="Latest BioModels Database publication">BioModels Database:
  An enhanced, curated and annotated resource for published
  quantitative kinetic models</a>.</p>
  </div>
  <div class="dc:license">
    <p>To the extent possible under law, all copyright and related or
  neighbouring rights to this encoded model have been dedicated to
  the public domain worldwide. Please refer to 
  <a href="http://creativecommons.org/publicdomain/zero/1.0/" title="Access to: CC0 1.0 Universal (CC0 1.0), Public Domain Dedication">CC0
  Public Domain Dedication</a> for more information.</p>
  </div>
</body>""" ;
    dc:title "Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer" .

<local:00001> rdfs:label "Francesco Pappalardo, Giulia Russo, Saverio Candido, Marzio Pennisi, Salvatore Cavalieri, Santo Motta, James A. McCubrey, Ferdinando Nicoletti & Massimo Libra. Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. PLOS ONE 11, 3 (2016)." ;
    dc:identifier <http://identifiers.org/doi/10.1371/journal.pone.0152104> .

